SK Biopharmaceuticals has announced that its joint venture, Mentis Care, has initiated a two-year collaborative research project with Emory University School of Medicine. The aim is to develop a versatile artificial intelligence (AI) model capable of utilizing both hospital-grade precision equipment (multichannel) and simple wearable devices for seizure detection and real-time prediction.
The joint research focuses on creating a transformer-based electroencephalogram (EEG) foundation model that functions consistently across various environments, ranging from the clinical standard 10-20 EEG system to reduced-channel wearable EEG devices.
This endeavor seeks to establish the technological groundwork necessary for continuous epilepsy monitoring in real-world settings.
Mentis Care will conduct this research using over 1 million hours of de-identified EEG data provided by Emory University School of Medicine.
The collaborative research encompasses several key areas: large-scale data curation and development of a standardized preprocessing pipeline, creation of a high-performance seizure detection foundation model, and validation across diverse patient groups and recording environments.
Lee Dong-hoon, CEO of SK Biopharmaceuticals, stated that SK Biopharmaceuticals is exploring new frontiers in patient care through AI-driven digital healthcare, extending beyond the innovative drug development. Through Mentis Care, it is committed to advancing patient-centered treatment innovations by integrating cutting-edge AI technology.
